ArticleBiology2026
Long-Term Corticosteroid-Induced Ocular Hypertension Model Produced by Topical Rinderon-A Ointment Application.
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Adverse effects associated with prolonged corticosteroid therapy are strongly associated with increased intraocular pressure (IOP), which may progress to iatrogenic glaucoma and irreversible blindness if left untreated. Developing reliable animal models is essential for investigating corticosteroid-induced ocular hypertension and evaluating potential therapeutic strategies. In this study, we established a simple and non-invasive rat model of corticosteroid-induced ocular hypertension using topical application of Rinderon-A ointment. Longitudinal IOP measurements were performed weekly using a Tono-Pen in conscious rats throughout the 11-week experimental period. Rinderon-A treatment resulted in sustained bilateral IOP elevation, with an initial increase observed at week 1 (28.4 ± 1.5 mmHg) and a maximal mean IOP of 31.2 ± 0.7 mmHg at week 10. Rinderon-A-treated eyes exhibited a sustained ocular hypertensive response throughout the experimental period. Collectively, this model provides a reproducible platform for studying corticosteroid-associated ocular hypertension and may facilitate future investigations of therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.